Generic companies for Atozet are interested in contractors

If there are 17 or less, the next generic company will also have the same price

Atozet

It is known that generic companies of the hyperlipidemia complex Atozet(Atorvastatin-Ezetimibe, Chong Kun Dang) will sign a consignment contract with Chong Kun Dang today (22nd).

 

Generic companies are paying attention to the number of final contractors and scrutinizing their strengths and weaknesses.

 

According to the industry on the 21st, Chong Kun Dang requested that the contract be revealed by the 18th after holding a consignment meeting on the 16th.

 

And it is reported that the final contract will be made on the 22nd.

 

Chong Kun Dang is recruiting 21 consignment companies.

 

However, generic companies seem to be struggling until the last minute because the number of companies may decrease at the time of the final contract.

 

However, most of them are expected to proceed with the contract.

 

The reason they are interested in the number of companies is that the price of drugs varies depending on the number.

 

In the new cascading drug price system, they can get high prices up to 20 items or less.

 

Drug prices drop from 21 in the order of listing.

 

However, if only 17 companies participate in the entrustment, A total of 19 items will be listed, including the original Atozet and Chong Kun Dang's incrementally modified drug(IMD).

 

Therefore, the next generic also has an opportunity to receive high drug prices.

 

The company entrusted with the first generic company, which is listed after the bioequivalence test, is also licensed at the same time, so it can receive high drug prices.

 

The industry expects that consignees such as Dongkoo Bio&Pharma will enter the market by applying for permission after the PMS expires in January next year.

 

Even if the entry order is late, it is an opinion that if the drug price is the same as that of Chong Kun Dang, it is not bad to belong to the generic group that goes through bioequivalence test.

 

This is because the commissioned production cost of generic group, which had bioequivalence test, is lower.

 

Due to such a complex formula, various theories are arising in the industry, such as a dual contract between Chong Kun Dang and Dongkoo Bio&Pharma.

 

However, no content has been confirmed yet.

 

The reason why it is so difficult to decide on generics for Atozet is that the cascade drug prices system, which has been in force since last July, are acting as a final blow.

 

According to this system, up to 20 items in the order of listing will receive 53.55% of the drug price compared to the original if the conditions such as bioequivalence test and the use of DMF are met.

 

However, starting from 21 generics, the order of approval became important as drug prices were calculated at 85% of the lowest price.

 

Generic for Atozet that have been tested for bioequivalence can apply for permission in time for the expiration of PMS in January next year.

 

However, Chong Kun Dang product that has undergone clinical trial is not generic, but is a drug for data-based re-evaluation, so it is expecting final approval in October.

 

Chong Kun Dang is conducting a commissioned generics consignment production project that recruits consignors through grant (data sharing) and can enter more quickly than generics.

 

Chong Kun Dang's products and delegated generics receive preferential drug prices over generics that have been tested for bioequivalence because they are listed in a faster order.